Integra Lifesciences Holdings (IART) EBT (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of EBT data on file, last reported at -$2.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 91.98% year-over-year to -$2.4 million; the trailing twelve-month figure through Mar 2026 stood at -$535.9 million (down 1145.0% YoY), and the FY2025 full-year result was -$563.5 million, down 2989.88% from the prior year.
• EBT declined to -$2.4 million in Q1 2026, from $4.3 million in the prior quarter.
• In the past five years, EBT ranged from a high of $64.2 million in Q4 2022 to a low of -$531.0 million in Q2 2025.
• A 5-year average of -$17.0 million and a median of $4.3 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 3396.56% in 2025 and surged 91.98% in 2026, its largest moves.
• Tracing IART's EBT over 5 years: stood at $64.2 million in 2022, then tumbled by 55.06% to $28.9 million in 2023, then decreased by 21.89% to $22.5 million in 2024, then tumbled by 80.88% to $4.3 million in 2025, then tumbled by 155.89% to -$2.4 million in 2026.
• Business Quant data shows IART's EBT at -$2.4 million in Q1 2026, $4.3 million in Q4 2025, and -$6.8 million in Q3 2025.